Ainos Goodwill and Intangible Assets 2010-2025 | AIMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ainos goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ainos goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$68.4B
Zoetis (ZTS)	$67.8B
Takeda Pharmaceutical (TAK)	$47.1B
Daiichi Sankyo, - (DSNKY)	$46.2B
BeOne Medicines - (ONC)	$33.9B
Sandoz Group AG (SDZNY)	$25.8B
Summit Therapeutics (SMMT)	$19.6B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$15.1B
United Therapeutics (UTHR)	$14.1B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.6B
Madrigal Pharmaceuticals (MDGL)	$8.2B
Corcept Therapeutics (CORT)	$7.6B
Grifols, S.A (GRFS)	$7.4B
Ionis Pharmaceuticals (IONS)	$6.8B
Stevanato Group S.p.A (STVN)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.3B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.1B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Crinetics Pharmaceuticals (CRNX)	$2.8B
Hypermarcas (HYPMY)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.4B
Ocular Therapeutix (OCUL)	$2.2B
Endo (NDOI)	$1.8B
Dyne Therapeutics (DYN)	$1.8B